Italia - Kiitaliano - Ministero della Salute

laboratorios hipra s.a. - eimeria maxima ceppo 013, eimeria mitis ceppo 006, eimeria praecox ceppo 007, eimeria acervulina ceppo 003, eimeria tenella ceppo 004 - eimeria maxima ceppo 013 - nd oocisti / dose; eimeria mitis ceppo 006 - nd oocisti / dose; eimeria praecox ceppo 007 - nd oocisti / dose; eimeria acervulina ceppo 003 - nd oocisti / dose; eimeria tenella ceppo 004 - nd oocisti / dose, eimeria maxima ceppo 013 - nd oocisti / dose; eimeria mitis ceppo 006 - nd oocisti / dose; eimeria tenella ceppo 004 - nd oocisti / dose; eimeria acervulina ceppo 003 - nd oocisti / dose; eimeria praecox ceppo 007 - nd oocisti / dose, eimeria maxima ceppo 013 - nd oocisti / dose; eimeria acervulina ceppo 003 - nd oocisti / dose; eimeria praecox ceppo 007 - nd oocisti / dose; eimeria tenella ceppo 004 - nd oocisti / dose; eimeria mitis ceppo 006 - nd oocisti / dose - coccidia

Italia - Kiitaliano - Ministero della Salute

programmi sanitari integrati srl - praziquantel, pirantel embonato - praziquantel - 20 mg; pirantel embonato - 230 mg - praziquantel, combinations

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - fluconazolum - capsule - fluconazolum 50 mg, colore.: e 132, excipiens pro capsula. - antifungini - synthetika

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - fluconazolum - capsule - fluconazolum 150 mg, excipiens pro capsula. - antifungini - synthetika

Uswisi - Kiitaliano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - fluconazolum - capsule - fluconazolum 200 mg, colore.: e 124, e 132, excipiens pro capsula. - antifungini - synthetika

Umoja wa Ulaya - Kiitaliano - EMA (European Medicines Agency)

merck sharp and dohme b.v - posaconazolo - candidiasis; mycoses; coccidioidomycosis; aspergillosis - antimicotici per uso sistemico - noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 e 5. 1):- invasive aspergillosisnoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections  4. 2 e 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. la refrattarietà è definito come la progressione di infezione o di mancata migliorare dopo un minimo di 7 giorni prima di dosi terapeutiche di una efficace terapia antimicotica. noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4. 2 e 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4. 2 e 5. 1):- invasive aspergillosisnoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4. 2 e 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. la refrattarietà è definito come la progressione di infezione o di mancata migliorare dopo un minimo di 7 giorni prima di dosi terapeutiche di una efficace terapia antimicotica. noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4. 2 e 5. 1):- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (gvhd) and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4. 2 e 5. 1):- invasive aspergillosis in patients with disease that is refractory to amphotericin b or itraconazole or in patients who are intolerant of these medicinal products;- fusariosis in patients with disease that is refractory to amphotericin b or in patients who are intolerant of amphotericin b;- chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- coccidioidomycosis in patients with disease that is refractory to amphotericin b, itraconazole or fluconazole or in patients who are intolerant of these medicinal products. la refrattarietà è definito come la progressione di infezione o di mancata migliorare dopo un minimo di 7 giorni prima di dosi terapeutiche di una efficace terapia antimicotica. noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2  years of age:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high  risk of developing invasive fungal infections;- haematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high  risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. please refer to the summary of product characteristics of noxafil oral suspension for use in oropharyngeal candidiasis.  noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5. 1):- aspergillosi invasiva in pazienti con malattia refrattaria ad amfotericina b o ad itraconazolo o in pazienti intolleranti a questi farmaci;- fusariosi in pazienti con malattia refrattaria ad amfotericina b o in pazienti che sono intolleranti di amfotericina b;- chromoblastomycosis e mycetoma in pazienti con malattia refrattaria ad itraconazolo o in pazienti che sono intolleranti di itraconazolo;- coccidioidomicosi in pazienti con malattia refrattaria ad amfotericina b, itraconazolo o fluconazolo o in pazienti intolleranti a questi farmaci;- candidiasi orofaringea: come terapia di prima linea in pazienti che hanno grave malattia o immunocompromessi, in cui la risposta alla terapia attuale è previsto per essere poveri. la refrattarietà è definito come la progressione di infezione o di mancata migliorare dopo un minimo di 7 giorni prima di dosi terapeutiche di una efficace terapia antimicotica. noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (aml) or myelodysplastic syndromes (mds) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- hematopoietic stem cell transplant (hsct) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. please refer to the summary of product characteristics of noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.

Umoja wa Ulaya - Kiitaliano - EMA (European Medicines Agency)

accord healthcare s.l.u. - voriconazolo - aspergillosis; candidiasis; mycoses - antimicotici per uso sistemico, derivati triazolo - voriconazolo è un ampio spettro, triazolo agente antimicotico ed è indicato negli adulti e nei bambini dai due anni e sopra come segue:il trattamento dell'aspergillosi invasiva;trattamento di candidaemia non neutropenici pazienti;trattamento di fluconazole-resistant gravi infezioni da candida invasive (tra cui c. krusei);il trattamento di gravi infezioni fungine causate da scedosporium spp. e fusarium spp.. voriconazolo accord deve essere somministrato principalmente a pazienti con progressiva, possibilmente infezioni life-threatening.

Umoja wa Ulaya - Kiitaliano - EMA (European Medicines Agency)

hikma farmaceutica (portugal) s.a. - voriconazolo - bacterial infections and mycoses; aspergillosis; candidiasis - antimicotici per uso sistemico - voriconazolo è un ampio spettro, triazolo agente antimicotico ed è indicato negli adulti e nei bambini di età compresa tra 2 anni e sopra come segue:il trattamento dell'aspergillosi invasiva;trattamento di candidaemia non neutropenici pazienti;trattamento di fluconazole-resistant gravi infezioni da candida invasive (tra cui c. krusei);il trattamento di gravi infezioni fungine causate da scedosporium spp. e fusarium spp.. voriconazolo deve essere somministrato principalmente a pazienti con progressiva, possibilmente infezioni life-threatening. profilassi di infezioni fungine invasive ad alto rischio allogenico di cellule staminali emopoietiche (hsct)destinatari.

Umoja wa Ulaya - Kiitaliano - EMA (European Medicines Agency)

pfizer europe ma eeig - voriconazolo - candidiasis; mycoses; aspergillosis - antimicotici per uso sistemico - voriconazolo, è un ampio spettro, triazolo agente antimicotico ed è indicato negli adulti e nei bambini di età compresa tra 2 anni e sopra come segue:il trattamento dell'aspergillosi invasiva;trattamento di candidaemianon-pazienti neutropenici;trattamento di fluconazole-resistant gravi infezioni da candida invasive (tra cui c. krusei);il trattamento di gravi infezioni fungine causate da scedosporium spp. e fusarium spp.. vfend deve essere somministrato principalmente a pazienti con progressiva, possibilmente infezioni life-threatening. profilassi di infezioni fungine invasive ad alto rischio allogenico di cellule staminali emopoietiche (hsct) destinatari.

Italia - Kiitaliano - Ministero della Salute

laboratorios calier s.a. - praziquantel, febantel, pirantel embonato - praziquantel - 50 milligrammo (i); febantel - 150 milligrammo (i); pirantel embonato - 50 milligrammo (i), febantel - 525 milligrammo (i); pirantel embonato - 175 milligrammo (i); praziquantel - 175 milligrammo (i), febantel - 525 milligrammo (i); aroma artificiale di manzo in polvere - nd ; pyrantel embonato - 175 milligrammo (i); praziquantel - 175 milligrammo (i), praziquantel - 175 mg; aroma artificiale di manzo in polvere - nd ; pyrantel embonato - 175 mg; febantel - 525 mg, pyrantel embonato - 50 mg; praziquantel - 50 mg; aroma artificiale di manzo in polvere - nd ; febantel - 150 mg, praziquantel - 175 mg; pyrantel embonato - 175 mg; aroma artificiale di manzo in polvere - nd ; febantel - 525 mg, praziquantel - 50 mg; pyrantel embonato - 50 mg; febantel - 150 mg; aroma artificiale di manzo in polvere - nd, aroma artificiale di manzo in polvere - nd ; febantel - 525 mg; pyrantel embonato - 175 mg; praziquantel - 175 mg, febantel - 525 mg; aroma artificiale di manzo in polvere - nd ; pyrantel embonato - - praziquantel, combinazioni